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Introduction
In 2001, the approval of imatinib, the ﬁrst-in-class tyrosine
kinase inhibitor (TKI) targeting BCR-ABL, transformed the
prognosis of patients with chronic-phase (CP) chronic mye-
loid leukemia (CML) from a life-threatening condition to a
manageable and chronic disease.1 Yet, despite satisfactory
outcomes, 33% of patients did not achieved optimal response
because of treatment resistance or intolerance.1 The identi-
ﬁcation of the predominant resistancemechanism (i.e., point
mutations in the kinase domain of Bcr-Abl) led to the
development of second-generation BCR-ABL TKIs (dasatinib,
nilotinib, and bosutinib, respectively, approved in 2006,
2007, and 2012) active against most of the BCR-ABL mutated
forms.2,3 Second-generation TKIs demonstrated no or little
improvement of the overall survival compared with imati-
nib,4–6 but two of these (i.e., dasatinib and nilotinib) improve
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Abstract Imatinib, the ﬁrst-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for
the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient
survival. Second- (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs
have been developed to be effective against BCR-ABL mutations making imatinib less
effective. However, these treatments have been associated with arterial occlusive events.
This review gathers clinical data and experiments about the pathophysiology of these
arterial occlusive events with BCR-ABL TKIs. Imatinib is associated with very low rates of
thrombosis, suggesting a potentially protecting cardiovascular effect of this treatment in
patients with BCR-ABLCML. This protective effectmight bemediated by decreased platelet
secretion and activation, decreased leukocyte recruitment, and anti-inﬂammatory or
antiﬁbrotic effects. Clinical data have guided mechanistic studies toward alteration of
platelet functions and atherosclerosis development, which might be secondary to
metabolism impairment. Dasatinib, nilotinib, and ponatinib affect endothelial cells and
might induce atherogenesis through increased vascular permeability. Nilotinib also impairs
platelet functions and induces hyperglycemia and dyslipidemia that might contribute to
atherosclerosis development. Description of the pathophysiology of arterial thrombotic
events is necessary to implement risk minimization strategies.
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surrogate outcomes and permit quicker and deeper achieve-
ment of molecular response, which is criteria to try treat-
ment cessation (i.e., MR4 or higher molecular response stable
for at least 2 years).7 Based on these results, dasatinib and
nilotinibwere approved in 2010 for frontlinemanagement of
CML, whereas bosutinib is used only after failure or intoler-
ance of ﬁrst-line BCR-ABL TKIs. Unfortunately, these treat-
ments were ineffective against a common mutation (14% of
all mutations) in the gatekeeper residue of BCR-ABL (i.e., the
T315Ia mutation),8–10 requiring the development of a third-
generation TKI (ponatinib), efﬁcient against this mutation.
Ponatinib is currently the only treatment active against the
T315I mutation and is therefore reserved for patients with
this mutation or for patients resistant to frontline
treatments.11
Since its approval, the ﬁrst-generation TKI, imatinib, has
demonstrated reassuring safety proﬁle, with low rate of
grade 3/4 adverse events and excellent tolerability.12,13
Conversely, new-generation BCR-ABL TKIs—nilotinib, dasa-
tinib, bosutinib, and ponatinib—are more recent and display
different safety proﬁle. Dasatinib, nilotinib, and ponatinib
are largely associated with ﬂuid retention and dasatinib
speciﬁcally induces high rate of pleural effusions.14–18 Nilo-
tinib induces metabolic disorders such as dyslipidemia and
hyperglycemia, whereas bosutinib safety proﬁle is mainly
characterized by gastrointestinal events (i.e., diarrhea, nau-
sea, vomiting).19,20 Finally, ponatinib has been rapidly asso-
ciated with high rate of vascular occlusion.21
Recently, meta-analyses of randomized clinical trials
established that ponatinib is not the only new-generation
TKI that increases the cardiovascular risk.22,23 The four new-
generation BCR-ABL TKIs increase the risk of vascular occlu-
sive events compared with imatinib, especially arterial
occlusive diseases, and this is in accordance with clinical
trial data.22–25 However, this cardiovascular risk is contro-
versy for dasatinib because of the low incidence (1.1 per 100
patient-year) of cardiovascular events in clinical trials.26,27
Recently, a large retrospective analysis of CP-CML patients
treated with BCR-ABL TKIs at theMDAnderson Cancer Center
conﬁrmed the increased risk of vascular occlusive events
with dasatinib.28 Another controversial point is the effect of
imatinib on the cardiovascular system. Indeed, imatinib is
associated with low risk of cardiovascular events and it was
therefore hypothesized that imatinib prevents their occur-
rence.29,30 Clinical data indicate that most patients develop-
ing arterial occlusive events with new-generation BCR-ABL
TKIs are high-risk patients, but cardiovascular events also
occurred in young and healthy patients. Additional informa-
tion on clinical safety of BCR-ABL TKIs is described in the
Supplementary Material (►Table S1). We assume that the
mechanism underlying arterial thrombosis with BCR-ABL
TKIs might be multiple. The predominance of arterial events
raised concerns about the impact of BCR-ABL TKIs on platelet
functions, atherosclerosis, and metabolism, and precluded
prothrombotic states to be responsible of these events.31
This review particularly focuses on the contribution of
glucose and lipid metabolism, atherosclerosis, and platelets
in the occurrence of cardiovascular events with new-gen-
eration TKIs. The last section discusses relevant off-targets
that might be implicated in the cardiovascular toxicity. The
discovery of the mechanism(s) by which arterial occlusive
events arose in CML patients would help in the management
of patients treated with BCR-ABL TKIs and implement risk
minimizationmeasures. Discovery of the pathophysiology of
these events in CML patients might also led to the develop-
ment of predictive biomarkers or to the development of new
therapies with no or reduced cardiovascular toxicity proﬁle
while keeping an unaltered efﬁcacy.
Impact on Platelet Functions
BCR-ABL TKIs are associated with both bleeding and throm-
botic complications. ►Table 1 describes experiments asses-
sing the impact of BCR-ABL TKIs on platelet production and
functions. Imatinib and dasatinib inducehemorrhagic events
in patients with CML. Interestingly, dasatinib-associated
hemorrhages occurred both in patients with and without
thrombocytopenia.32 In vitro and in vivo investigations
demonstrated that dasatinib affects both platelet functions
(i.e., platelet aggregation, secretion, and activation) and
platelet formation by impairment of megakaryocyte migra-
tion.33–36 Furthermore, dasatinib decreases thrombus for-
mation in vitro, in vivo, and ex vivo,34 and decreases the
number of procoagulant platelets (i.e., phosphatidylserine-
exposing platelets).35 Several dasatinib off-targets are impli-
cated in platelet signaling and functions including members
of the SFKs (e.g., Src, Lyn, Fyn, Lck, and Yes) (►Fig. 1).37,38
However, SFKs are also inhibited by bosutinib without dis-
turbance of platelet aggregation and adhesion. Dasatinib also
inhibits Syk, BTK, and members of the ephrin familyb (e.g.,
EphA2), all known to be involved in platelet functions.
Experimental assessments of platelet functions with ima-
tinib demonstrate less pronounced effects on platelets. Ima-
tinib inhibits platelet aggregation only at high doses,34 and
does not interfere with platelet aggregation in vivo.39 How-
ever, in vitro studies also indicate decreased platelet secre-
tion and activation by imatinib.34 The mechanism by which
imatinib inhibits platelet functions is unknown. Oppositely
to dasatinib, imatinib does not inhibit SFKs, ephrins, BTK, and
Syk. A hypothesis also suggests that imatinib induces bleed-
ing disorders because of BCR-ABL rearrangements in mega-
karyocytic cell lines, leading to clonal expansion of
dysfunctional megakaryocytes.40
Even if ponatinib induces very few bleeding disorders,
assessment of primary hemostasis in CML patients demon-
strated that ponatinib induces defect in platelet aggregation.
This impairment was found at all ponatinib dosage, in
patients with or without low platelet counts.41 These resultsa T315I: Substitution at position 315 in BCR-ABL from a threonine to
an isoleucine. This substitution alters the structure of the ATP-
binding pocket and eliminates a crucial hydrogen bond required for
binding of first- and second-generation TKIs.
b Ephrin family: Members of this family are involved in platelet
spreading, adhesion to fibrinogen and platelet secretion.
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were in accordance with in vitro studies which previously
demonstrated similar characteristics than dasatinib (i.e.,
decrease of platelet spreading, aggregation, P-selectin secre-
tion, and phosphatidylserine exposure).35,42 However, in
vitro assays tested ponatinib at 1 µM, a dose far higher
than the concentration observed in patients on treatment.43
Nilotinib and bosutinib are not associated with bleeding
disorders in CMLpatients. First in vitro studies demonstrated
little or no effect on platelet aggregation and activation with
these two TKIs.36,39,44 However, recent experiments
described prothrombotic phenotype of platelets induced
by nilotinib, with increase of PAR-1c–mediated platelet
secretion, adhesion, and activation, without disturbing pla-
telet aggregation.34 Additional studies demonstrated that
nilotinib increases secretion of adhesivemolecules as well as
thrombus formation and stability ex vivo.34
To summarize, dasatinib and imatinib induce hemorrha-
gic events through alteration of platelet functions, but the
molecular mechanism needs to be better determined. Pona-
tinib also impairs platelet functions. Therefore, no current
data involve platelets in the pathogenesis of arterial throm-
bosis occurring with dasatinib and ponatinib. Oppositely,
nilotinib might induce arterial thrombosis through altera-
tion of platelet secretion, adhesion, and activation.
Metabolic Dysregulation
Glucose Metabolism
BCR-ABL TKIs have contradictory effect on glucose metabo-
lism. Imatinib and dasatinib improve glucose metabolism
and type 2 diabetes management in CML patients (i.e.,
decrease of antidiabetic drug dosage and reversal of type 2
diabetes).14,45–49 This clinical proﬁle is in accordancewith in
vivo studies in which imatinib is effective to prevent the
development of type 1 diabetes in prediabetic mice, without
impacting the adaptive immune system.50 Therefore, imati-
nib is currently tested in clinical trials for patients suffering
from type 1 diabetes mellitus (NCT01781975). The mechan-
ism(s) by which dasatinib and imatinib improve glucose
Fig. 1 Signaling pathways supporting platelet adhesion, activation, and aggregation. Tyrosine kinases are involved in several pathways and
contribute to platelet adhesion, aggregation, and activation. Important players in platelet signaling are members of the Src family kinases;
particularly Lyn, Fyn, and cSRC. These three tyrosine kinases are inhibited by dasatinib which might explain platelet dysfunction encountered
with this treatment. Additionally, dasatinib also inhibits BTK, Syk, EphA4, and EphB1—four tyrosine kinases involved in platelet activation and
aggregate stabilization. 5HT, 5-hydroxytryptamine; ADP, adenosine diphosphate; Btk, Bruton’s tyrosine kinase; Ca, calcium; Eph, ephrin; FcR, Fc
receptor; GP, glycoprotein; PAR, protease-activated receptor; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C; TXA2, thromboxane A2;
vWF, Von Willebrand factor.
c PAR-1: protease-activated receptor 1. PAR receptors mediate
cellular effects of thrombin in platelets and endothelial cells.
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metabolism remains unknown. Global hypotheses suggest
that imatinib increases peripheral insulin sensitivity, pro-
motes β-cell survival, or decreases hepatic glucose produc-
tion (►Fig. 2).51–54 This latter hypothesis (i.e., decreased
hepatic glucose production by imatinib) is not currently
the preferred theory, whereas it was demonstrated that
imatinib weakly affects hepatic glucose production.51 Sev-
eral targetsmight be involved in thismetabolic effect. PDGFR
has already been linked with type 1 diabetes reversal.50
Hägerkvist et al hypothesized that c-Abl inhibition by ima-
tinib promotes β-cell survival through activation of NF-κB
signaling and inhibition of proapoptotic pathways
(►Fig. 2).53,54 Inhibition of c-Abl in β-cells might also
increase insulin production and contribute to the glucose
regulation by imatinib.55 It was also speculated that imatinib
decreases insulin resistance in peripheral tissues due to c-
Abl-dependent JNK inactivation.d,51 Similar hypotheses
might be translated to dasatinib because of the similar off-
target inhibitory proﬁle (i.e., dasatinib also inhibits c-Abl and
PDGFR). It was hypothesized that imatinib and dasatinib
impact glucose metabolism through reduced adipose
mass.51,56 However, clinical data do not demonstrate weight
loss in CML patients and do not favor this hypothesis. In both
imatinib- and dasatinib-treated patients, increased circulat-
ing adiponectine level correlates with decreased insulin
resistance.57,58 This correlation might be explained by the
translocation of the glucose transporter GLUT4f from the
cytoplasm to the cell membrane following adiponectin sig-
naling.59 Additionally, adiponectin has been related to
decreased hepatic glucose production which could be an
additional mechanism by which imatinib and dasatinib
improve glucose metabolism.60 It was speculated that the
raise of adiponectin level with imatinib and dasatinib is the
consequence of increased adipogenesis subsequent to
PDGFR inhibition.61
Fig. 2 Effects of BCR-ABL TKIs on glucose metabolism. Imatinib and dasatinib possess hypoglycemic effects, whereas nilotinib increases blood
glucose level and diabetes development. The ﬁgure describes glucose metabolism and boxes contain emitted hypotheses for effects of imatinib,
dasatinib, and nilotinib on glucose metabolism. Four major hypotheses have been emitted including impact on insulin production by β-cells, β-
cell survival, peripheral insulin sensitivity, and hepatic glucose production. ABL, Abelson; FAK, focal adhesion kinase; GLUT, glucose transporter;
IRS-1, insulin receptor substrate 1; JNK, c-Jun N-terminal kinases; MEKK1, MAPK/ERK kinase kinase 1; NF-κB, nuclear factor-kappa B; PDK1,
pyruvate dehydrogenase kinase 1; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species.
d JNK: c-Jun N-terminal kinases. JNK is responsive to stress stimuli
and mediates insulin resistance through inhibition of insulin
receptor substrate.
e Adiponectin is a protein regulating glucose metabolism. Adipo-
nectin increases peripheral insulin sensitivity by improving
glucose uptake.
f GLUT4: Glucose transporter type 4. GLUT4 is an insulin-regulated
glucose transporter expressed in peripheral tissues.
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Oppositely to imatinib and dasatinib, case reports and
clinical trials indicate that nilotinib increases blood glucose
level and promotes diabetes mellitus.62–65 Indeed, 20% of
nilotinib-treated patients developed diabetes after 3 years of
treatment,65whereas 29% of patients suffer from increase of
fasting glucose after 1 year of therapy.64 However, no varia-
tions of glycated hemoglobin were reported.64,65 Clinical
data indicate no direct effect of nilotinib on β-cells, but
suggest fasting insulin increase, fasting C-peptide decrease,
and an increase of HOMA-IR values (i.e., a model to assess
insulin resistance).64,66,67 Therefore, the preferred hypoth-
esis to explain the development of hyperglycemia is the
manifestation of insulin resistance. Weakened insulin secre-
tion occurred sometimes, but it is likely that this impairment
is the consequence of β-cell exhaustion.68 However, in vitro
experiments demonstrated inhibitory effect of nilotinib on
pancreatic cell growth.69 Breccia et al proposed an additional
hypothesis linking development of hyperglycemia and body
mass index. They suggested that the development of hyper-
glycemia might be the consequence of increase fat level
tissue resulting in decrease peripheral insulin sensitivity.70
However, dietetic measures to restrict glucose exogenous
uptake in patients who developed hyperglycemia were not
successful,63 and nilotinib does not induce changes in patient
body weight.71 Little is known regarding the mechanism by
which nilotinib induces insulin resistance. Racil et al sug-
gested that peripheral insulin resistance is mediated by c-Abl
inhibition which is involved in insulin receptor signaling
(►Fig. 2).67 This hypothesis is contrary to the hypothesis
described with dasatinib and imatinib in which c-Abl
enhances insulin sensitivity through c-Abl inhibition. These
two hypotheses describe different pathways involving c-Abl
but with opposite outcomes. To date, no hypothesis is pre-
ferred and additional studies are required to understand the
opposite effect on glucose metabolism between TKIs,
whereas both have been attributed to c-Abl inhibition.
Interestingly, Frasca et al described opposite role of c-Abl
in insulin signaling depending on the receptor involved, the
signaling pathway, and the cell context.72 Similar investiga-
tions should be performed in the context of c-Abl inhibition
by BCR-ABL TKIs. For bosutinib and ponatinib, little is known
regarding their impact on glucosemetabolism, but no drastic
changes in glucose proﬁle has been reported during clinical
trials.
Fig. 3 Effects of BCR-ABL TKIs on lipid metabolism. Several hypotheses have been emitted to explain the imatinib-induced hypolipidemic effect.
Imatinib regulates expression of genes involved in lipid metabolism: Apobec1 that regulates ApoB expression through the introduction of a stop
codon into ApoBmRNA (ApoB is essential for VLDL production), and LDLR that is implicated in lipid clearance. Imatinib-induced PDGFR inhibition
inﬂuences LPL synthesis and dysregulates LRP. Dasatinib and nilotinib increase cholesterol plasma level through an unknown mechanism. Global
hypotheses can be emitted and include increased hepatic lipid synthesis (possibly related to hyperinsulinemia) and decreased lipid clearance
through LDLR functional defect or decreased LPL synthesis. ABC, ATP-binding cassette; C, cholesterol; CETP, cholesteryl ester transfer protein;
CM, chylomicron; FA, fatty acid; HMGCoA reductase, hydroxymethylglutaryl-CoA reductase; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; LDLR, low-density lipoprotein receptor; LPL, lipoprotein lipase; LRP, lipoprotein receptor-related protein; PDGFR, platelet-
derived growth factor receptor; VLDL, very low-density lipoprotein.
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e74
Lipid Metabolism
Similarly with glucose metabolism, effects on lipid metabo-
lism are conﬂicting betweenTKIs. Oppositely to in vivo study
which demonstrated no impact of imatinib on total choles-
terol and triglycerides levels in diabetic mice,29 imatinib is
associated in CML patients with a rapid and progressive
decrease of cholesterol and triglycerides levels.66,73–75 First
hypothesis relates the inhibition of PDGFR by imatinib
(►Fig. 3). PDGFR is involved in the synthesis of the lipopro-
tein lipase (LPL) and in the regulation of the lipoprotein
receptor-related protein (LRP).73,74 However, all BCR-ABL
TKIs possess inhibitory activity against PDGFR but do not
share this positive impact on lipid proﬁle. Recently, Ellis et al
described that imatinib impairs gene expression of proteins
involved in plasma lipid regulation. Indeed, in in vitro model
of CML cells, imatinib affects gene expression of four genes
implicated in lipid synthesis (HMG-CoA reductaseg gene and
apobec1h), lipid clearance (LDLR genei) and in exchange of
lipids from very low-density lipoprotein (VLDL) or low-
density lipoprotein (LDL) to high-density lipoprotein (HDL)
(CETPj gene). However, these studies were performed in a
model of CML cells and need to be conﬁrmed in more
relevant models (e.g., primary cell lines, hepatocytes).76
Franceschino et al suggested that imatinib decreases diar-
rhea-related lipid absorption due to inhibition of c-kit in
interstitial Cajal cells (i.e., c-kit signaling is critical for the
survival and development of these cells).73 However,
this hypothesis is unlikely, few patients (3.3%) developed
grade 3/4 diarrhea, and patients treated with interferon-α
and cytarabine developed diarrhea at a same rate and do not
present lipid level reduction in the phase 3 clinical trial
(NCT00333840).
Oppositely, dasatinib and mostly nilotinib are associated
with an increase of cholesterol level.26,66,77Nilotinib induces
quick rise of total cholesterol, HDL, and LDL (i.e., within 3
months). Nilotinib-induced dyslipidemia are responsive to
statin and lipid level normalized after nilotinib discontinua-
tion.78 To date, the mechanism by which dasatinib and
nilotinib impact lipid metabolism is unknown. Future
researches should determine how these treatments induce
dyslipidemia. Global hypotheses could be formulated and
include an increase of lipid synthesis that might
be secondary to insulin resistance and hyperinsulinemia.
This hypothesis is particularly relevant with nilotinib and it
is also associated with hyperglycemia. Dasatinib and niloti-
nib might also decrease blood lipid clearance (e.g., distur-
bance of LDLR and LPL synthesis). The development of
dyslipidemia might contribute to the occurrence of arterial
occlusive events that occurred with nilotinib and dasatinib.
However, the relationship between impaired lipid metabo-
lism and cardiovascular occlusive events is unknown with
BCR-ABL TKIs, and there is no indication that correct man-
agement of lipidmetabolism can prevent arterial thrombosis
(e.g., stenosis occurred in a nilotinib-treated patient despite
the management of its hyperlipidemia through statin treat-
ment).79 On their side, bosutinib and ponatinib do not
disturb lipid metabolism.78,80
Effects on Atherosclerosis
Endothelial Dysfunction
►Fig. S1 in the Supplementary Material details the role of
endothelial cells (ECs) in atherosclerosis. Several in vitro and
in vivo experiments assess the impact of imatinib on EC
viability and functions (►Table 2). These studies demon-
strate that imatinib does not affect EC viability nor induce
apoptosis but increases EC proliferation.39,81–84 Only one
study reports a proapoptotic effect of imatinib on ECs, but
their experiments were performed on a cell line (i.e., EA.
hy926 cells),85 a model less reliable than primary cultures
(e.g., HUVEC,k HCAECl). In vitro studies also assessed the
effect of imatinib on EC functions. In these studies, imatinib
does not inﬂuence adhesion molecule expressions (i.e.,
ICAM-1m and VCAM-1n), EC migration, reactive oxygen
species (ROS) production, nor angiogenesis.81,82,85–87 Let-
siou et al suggested that imatinib decreases EC inﬂammation
by decreasing the secretion of proinﬂammatorymediators.86
The impact of imatinib on endothelial permeability is not
clear. Indeed, in vitro studies demonstrate that imatinib
increases endothelial permeability by decreasing the level
of plasma membrane VE-cadherin,o,85,86 whereas in vivo
experiments indicate decreased vascular leak following ima-
tinib treatment in a murine model of acute lung injury.88
Additionally, imatinib has been tested in patients suffering
from acute lung injury, a disease characterized by vascular
leakage, and demonstrate promising clinical efﬁcacy. There-
fore, imatinib might positively affect atherogenesis by
decreasing endothelial inﬂammation and reducing vascular
leakage.
Nilotinib and ponatinib reduce EC proliferation andmight
impaired endothelial regeneration.39,82,89,90 Additionally,
ponatinib induces EC apoptosis, although it is well recog-
nized that high glucose concentration induces EC death,91
suggesting that nilotinib might, by this intermediary, affect
EC viability. Moreover, clinical data indicate that dasatinib
induces pulmonary arterial hypertension, whereas imatinib
is possibly beneﬁcial in this disease.92,93 This pathology is
initiated by dysfunction or injury of pulmonary ECs.87
g HMGCoA reductase: 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase. HMGCoA reductase catalysis is the conversion of
HMG-CoA to mevalonic acid, an essential step in cholesterol
synthesis.
h Apobec1: Apolipoprotein B mRNA editing enzyme catalytic subunit
1. Apobec1 introduces a stop codon into ApoB mRNA.
i LDLR: Low-density lipoprotein receptor. This cell surface receptor
mediates LDL endocytosis.
j CETP: Cholesteryl ester transfer protein.
k HUVEC: Human umbilical vein endothelial cells.
l HCAEC: Human coronary artery endothelial cells.
m ICAM-1: Intercellular adhesion molecule 1. ICAM-1 stabilizes
leukocyte-endothelial cell adhesion and facilitates leukocyte
transmigration.
n VCAM-1: Vascular cell adhesion molecule 1. VCAM-1 mediates
rolling-type and firm adhesion of leukocyte.
o VE-cadherin: Vascular endothelial cadherin. VE-cadherin is a cell–
cell adhesion molecules and implies in endothelial junctions.
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Therefore, in vivo and in vitro studies investigated effect of
imatinib and dasatinib on pulmonary ECs and demonstrate
that dasatinib induces apoptosis on pulmonary ECsmediated
by increased mitochondrial ROS production.87 Future
researches should assess if this effect is also found in arterial
ECs and ROS production should also be tested with other
new-generation BCR-ABL TKIs.
In addition to their effect on EC viability, nilotinib and
ponatinib also inﬂuence EC functions, inhibit their migra-
tion, and decrease angiogenesis.39,82 It was suggested that
the antiangiogenic effect of ponatinib is the consequence of
VEGFRp inhibition, but this hypothesis cannot explain the
antiangiogenic effect of nilotinib (i.e., nilotinib does not
inhibit VEGFR).82 Nilotinib also increases adhesion molecule
expressions (i.e., ICAM-1, VCAM-1, and E-selectin) in vitro,39
suggesting that nilotinib might increase leukocyte recruit-
ment. However, further experiments are needed to validate
this hypothesis (e.g., assessment of endothelium permeabil-
ity and transendothelial migration). Dasatinib also induces
endothelium leakage in vitro, and the RhoA-ROCKq pathway
is involved in this phenomenon.94 It was demonstrated that
RhoA activation induces the phosphorylation of myosin light
chain that increases the actomyosin contractibility and dis-
rupt endothelial barrier.94 Therefore, increased endothelium
permeability is a potential mechanism by which dasatinib
and nilotinib promote atherosclerosis development and
arterial thrombosis. Likewise, it is plausible that ponatinib
affects endothelium integrity because of its inhibitory activ-
ity against VEGFR, which is recognized as a permeability-
inducing agent. Additional hypotheses suggest that inhibi-
tion of Abl kinase (i.e., Argr and c-Abl) and PDGFR might also
be implicated in vascular leakage.85 Finally, Guignabert et al
demonstrated that both in rats and in CML patients taking
dasatinib, there is an increase of soluble adhesionmolecules,
which arewell-knownmarkers of endothelial dysfunction.87
Inﬂammation
►Fig. S2 in the Supplementary Material describes the role of
immune cells and inﬂammation process during
atherosclerosis. ►Table 3 summarizes in vitro studies that
investigate impacts of BCR-ABL TKIs on survival, prolifera-
tion, andmajor functions ofmonocytes,macrophages, and T-
lymphocytes. Globally, in vitro studies demonstrate that
imatinib inhibits the development and maturation of mono-
cytes and alters monocyte functions.95,96 Imatinib decreases
production of proinﬂammatory cytokines (i.e., TNF-αs and
IL-6t) and diminishes the potential of monocytes to phago-
cytose.97,98 These impacts on monocyte functions are pos-
sibly related to c-fmsu inhibition.99 Imatinib also inhibits
macrophage functions in vitro. Imatinib decreases lipid
uptake without impacting the lipid efﬂux and decreases
activity and secretion of two matrix metalloproteinases
(MMPs; i.e., MMP-2 and MMP-9v) on a posttranscriptional
level.100 Additionally, imatinib inhibits T-lymphocyte acti-
vation and proliferation and decreases proinﬂammatory
cytokines secretion (i.e., IFN-γw).101 The inhibition of mono-
cyte, macrophage, and T-cell functions by imatinib might
prevent the development of atherosclerosis or reduce the
risk of atherosclerotic plaque rupture.
Effects of new-generation TKIs on inﬂammatory cells
were less studied, but ﬁrst experiments indicate similarities
with imatinib about its impact on monocytes and macro-
phages. Both dasatinib and nilotinib have similar inhibitory
proﬁle on macrophage-colony formation that has been
linked to CSFR inhibition.96,102 Dasatinib also possesses
anti-inﬂammatory functions by attenuating proinﬂamma-
tory cytokines production (i.e., TNF-α, IL-6, and IL-12x) by
macrophages and increasing production of anti-inﬂamma-
tory mediator (i.e., IL-10y).103 These effects are thought to be
mediated by SIKz inhibition, a subfamily of three serine/
threonine kinases that regulate macrophage polariza-
tion.103,104 Finally, dasatinib is associated with decreased
T-cell functions and particularly it decreases the production
of proinﬂammatory cytokines (e.g., TNF-α, IFN-γ) and che-
motactic mediators.105 Nilotinib and bosutinib also possess
anti-inﬂammatory activity and decrease cytokine produc-
tion and T-cell activation.103,106 Inhibition of Lck,ai a tyrosine
kinase implicated inT-cell receptor signaling, is implicated in
the impairment of T-cell functions by dasatinib and niloti-
nib.107,108 It has been hypothesized that nilotinib decreases
mast cell activity through c-kit inhibition,62,109 which might
result in a decrease of the vascular repair system.39,62
Clinical proﬁle of nilotinib in patients with CML consolidates
this hypothesis and demonstrates a decreased of mast cell
level.39 However, similar decreased of mast cell is also
reported with imatinib without high rate of arterial
thrombosis.110
Globally, BCR-ABL TKIs possess reassuring proﬁle on
inﬂammatory cells. However, impact of new-generation
TKIs on several functions of macrophages have not been
assessed (e.g., MMP secretion and activity, lipid uptake, and
p VEGFR: Vascular endothelial growth factor. This protein plays
major roles in vasculogenesis and angiogenesis.
q RhoA-ROCK: Ras homolog gene family, member A—Rho-associated
protein kinase. Rho-kinase regulates cytoskeletal reorganization,
cell migration, cell proliferation, and survival.
r Arg: Abelson-related gene (also known as ABL2). Arg possesses
cytoskeletal-remodeling functions.
s TNF-α: Tumor necrosis factor alpha. This cytokine is mainly
involved in systemic inflammation and regulates immune cells.
t IL-6: Interleukin 6. IL-6 is a proinflammatory cytokine secreted by
T-cells and macrophages to stimulate immune response.
u CSFR: Colony-stimulating factor receptor. CSFR drives growth and
development of monocytes.
v MMP-2 and MMP-9 are two proteases capable of degrading
extracellular matrix components. These two MMPs are the main
proteases involved in atherogenesis.
w IFN-γ: Interferon gamma. IFN-γ is involved in innate and adaptive
immunity and activates macrophages.
x IL-12: Interleukin 12. IL-12 is involved in T-cell differentiation and
functions.
y IL-10: Interleukin 10. IL-10 exerts immunoregulation and regulates
inflammation.
z SIK: Salt-inducible kinase. SIKs regulate production of anti- and
proinflammatory cytokines.
ai Lck: Lymphocyte-specific protein tyrosine kinase. Lck is mostly
involved in T-cell maturation.
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foam cell formation), whereas effect of ponatinib on inﬂam-
matory cells is unknown. The assessment of lipid uptake and
foam cell formation is particularly relevant with new-gen-
eration TKIs because there are numerous interactions
between TKIs and ABC transporters.aii,111,112
Fibrous Cap Thickness
►Fig. S3 in the Supplementary Material describes the
mechanism by which atherosclerotic plaque ruptures and
induces arterial thrombosis. ►Table 4 summarizes in vitro
and in vivo experiments performed on VSMCs and ﬁbro-
blasts. Imatinib decreases VSMC proliferation and growth
but results are conﬂicting about its impact on apoptosis.
Some studies demonstrate no impact on SMC apoptosis,
whereas others indicate increased SMC death.83,113–116 Ima-
tinib also affects VSMC functions and decreases their migra-
tion and LDL binding, inducing decreased LDL retention by
the sub-endothelium.113,117 Imatinib also exerts negative
effect on the synthesis of major ECM components (type I
collagen and ﬁbronectin A) by ﬁbroblasts, correlating to
decreased ECM accumulation in vivo.118 The impact of
imatinib on SMCs is thought to be mediated by PDGFR
inhibition,114 which is involved in several VSMC functions
including VSMC survival and plasticity.113 Subsequent to the
hypothesis that imatinib inhibits PDGFR signaling, prevents
abundant SMC and ﬁbroblast proliferation, and inhibits
abundant ECM accumulation, imatinib has been tested for
themanagement of several ﬁbrotic diseases (e.g., dermal and
liver pulmonary ﬁbrosis, systemic sclerosis).30,118,119 Imati-
nib successfully acts on pulmonary ﬁbrosis and pulmonary
arterial hypertension (i.e., a disease involving vascular remo-
deling mediated by pulmonary SMC proliferation),93,114 and
has beneﬁcial activity in sclerotic chronic graft-versus-host
disease.120 Finally, imatinib was tested in vivo for the pre-
vention of cardiovascular diseases and demonstrates efﬁcacy
for the treatment of myocardial ﬁbrosis by reducing ECM
component synthesis (i.e., procollagen I and III).30 In a rat
model, imatinib successfully inhibits stenosis after balloon
injury and presents interest in intimal hyperplasia and
stenosis after bypass grafts.115,116,121–123 Imatinib also suc-
cessfully prevents arterial thrombosis following microvas-
cular surgery in rabbits.124 Imatinibwas also encompassed in
a stent but do not demonstrate efﬁcacy in restenosis
prevention.84
Impact of new-generation TKIs on ﬁbrosis was less stu-
died but demonstrate similar inhibitory effect on VSMCs and
ﬁbroblasts. Indeed, dasatinib inhibits PDGFR more potently
than imatinib,113 and the hypothesis that dasatinib prevents
restenosis similarly with imatinib was emitted. Therefore, a
patent has been ﬁled claiming the use of dasatinib for the
prevention of stenosis and restenosis.125 Compared with
imatinib, dasatinib has additional off-targets and is able to
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aii ABC transporter: ATP-binding cassette transporters. ABCG1 and
ABCA1 are implicated in macrophage reverse cholesterol transport.
Their deficiency leads to foam cell formation and atherosclerosis
development.
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inhibit Src,aiii a kinase involved in dermal ﬁbrosis in addition
to PDGFR.126 Therefore, dasatinibwas tested in patients with
scleroderma-like chronic graft-versus-host disease, a disease
resulting from inﬂammation and progressive ﬁbrosis of the
dermis and subcutaneous tissues, and ﬁrst results are
encouraging.126 Nilotinib also appears to be clinically efﬁ-
cient in scleroderma-like graft-versus-host disease by redu-
cing collagen expression.127 Finally, nilotinib was tested in
vivo for the treatment of liver ﬁbrosis and demonstrates
decreased ﬁbrotic markers and inﬂammatory cytokines (IL-
1α, IL-1β, IFN-γ, IL-6).128 However, only low-dose nilotinib
was found to be efﬁcient against ﬁbrosis and normalized
collagen content.128 This lack of antiﬁbrotic effect at higher
doses might be explained by inhibition of additional off-
targets by nilotinib that affect the beneﬁt of low-dose
nilotinib against ﬁbrosis. Arterial thrombosis occurring
with dasatinib and nilotinib are probably not the conse-
quence of VSMC impairment, but investigations should be
performed on VSMCs rather than on ﬁbroblasts. Additional
investigations are warranted to complete impact of BCR-ABL
TKIs on VSMC functions (e.g., VSMC apoptosis, proliferation,
and migration) and conﬁrm their safety toward VSMCs.
Off-targets
BCR-ABL TKIs bind the highly conserved ATP binding site and
arethereforenot veryspeciﬁc toBCR-ABL andpossessmultiple
cellular targets (kinases and nonkinase proteins).129,130 This
allowed the possibility to exploit them in other indications
(e.g., PDGFR inhibitionby imatinib isused inBCR-ABL-negative
chronic myeloid disorders),131 but this may also induce toxi-
cities and side effects.129 The development of arterial throm-
botic events with new-generation BCR-ABL TKIs is likely to be
related to inhibition of off-targets, as described throughout
this review. ►Fig. 4 describes inhibitory proﬁles of imatinib,
dasatinib, nilotinib, bosutinib, and ponatinib. Globally, imati-
nib is the most selective BCR-ABL TKIs, whereas dasatinib and
ponatinib inhibit numerous off-targets.
However, inhibitory proﬁles are difﬁcult to determine and
several researches published discrepancies. For conﬂicting
results, a conservative approach has been applied in ►Fig. 4,
but supplementary information (►Table S2) describes the tyr-
osine kinase selectivity proﬁle of the ﬁve BCR-ABL TKIs and
indicates divergences between studies.43,130,132–134 These dis-
crepancies can be explained by the difference in drug concentra-
tionandmethodologies.Todate, severalmethodshavebeenused
todetermine inhibitoryproﬁle of BCR-ABLTKIs including invitro
kinase assay,133–135 kinase expression in bacteriophages,136 and
Fig. 4 Speciﬁcity of imatinib, dasatinib, nilotinib, and ponatinib toward tyrosine kinases. Green, yellow, red, and blue circles contain tyrosine
kinase inhibited by dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Tyrosine kinases in white represent imatinib off-targets. This ﬁgure
summarizes results from 13 experiments.39,43,130,132–137,156–159 In case of conﬂictual results between studies, a conservative approach has
been applied. Additional information is provided in the Supplementary Material.
aiiiSrc is involved in angiogenesis and cell survival and proliferation.
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afﬁnity puriﬁcation methods combined with mass spectropho-
tometry.130,132 However, all these methods suffer from caveats,
including the incompatibility to perform live-cell studies. A cell-
permeablekinaseprobewasdevelopedtoﬁgureoutthisproblem,
butthisassayisstill limitedbythenumberofoff-targettested(i.e.,
it requires to predeﬁne tested off-targets) and therefore, the
missing of targets is possible.137 For this reason, the inhibitory
activityofeachTKIhasnotbeen tested towardall tyrosinekinase
and►Fig. 4 includes onlyoff-targets forwhich at least oneof the
ﬁveBCR-ABLTKIhasbeentested.Thus, inhibitoryproﬁlesneedto
be carefully considered and it has to keep in mind that BCR-ABL
TKI metabolites may possess activity against supplemental off-
targets.
As described over this review, PDGF signaling has count-
less effects on several cells and tissues and is involved in
several proatherogenic mechanisms (e.g., adipogenesis, vas-
cular leakage, VSMC viability, and functions) and vascular
homeostasis, which led to the suggestion of its implication in
the potential beneﬁcial cardiovascular effect of imati-
nib.116,123,138 However, dasatinib, nilotinib, and ponatinib
also inhibit PDGFR but increase the risk of arterial occlusive
events. This difference of clinical outcome might be
explained by the concentration of BCR-ABL TKIs necessary
to obtain a same degree of PDGFR inhibition.43 Indeed, Rivera
et al reported that when adjusted to the maximum serum
concentration, imatinib inhibits more profoundly PDGFR
than dasatinib, nilotinib, and ponatinib.43 Therefore, at
effective concentration, it is probable that the degree of
PDGFR inhibition is too low with dasatinib, nilotinib, and
ponatinib to obtain the beneﬁcial effect of PDGFR inhibition
on atherosclerosis. Another possible hypothesis concerns the
less conclusive speciﬁcity of new-generation TKIs which
leads to inhibition of additional off-targets that might coun-
terbalance the positive effect of PDGFR inhibition.
Other tyrosine kinases have been incriminated in the occur-
renceof arterial thrombosiswithnew-generationTKIs. DDR-1aiv
possesses functions in vascular homeostasis, atherogenesis,
and is expressed in pancreatic islet cells. However, and
similarly with PDGFR, it is inhibited by all BCR-ABL
TKIs.26,62 Other hypotheses include impairment of VEGF
signaling by ponatinib43,90 or the inhibition of several ephrin
receptors by new-generation TKIs but not by imatinib which
might inhibit monocyte recruitment.139 Finally, it has
been suggested that the inhibition of c-Abl itself is implica-
ted in the increase of the cardiovascular risk. Indeed, ima-
tinib possesses lower inhibitory effect on c-Abl than
new-generation TKIs, which might further explain the
difference in cardiovascular safety.43 Additionally, c-Abl
modulates Tie-2,av a tyrosine kinase that possesses impor-
tant effect on endothelial cell function, angiogenesis, and
inﬂammation.140,141
Perspectives and Conclusions
This review summarizes the data underlying the potential
preventive effect of imatinib on the occurrence of arterial
thrombosis. Globally, in vitro and in vivo experiments
demonstrate that imatinib possesses antiplatelet activity,
hypolipidemic and hypoglycemic effects, and inhibits
inﬂammation and atherosclerosis development in several
cell types (i.e., decreases of inﬂammatory cell and VSMC
functions and increased vascular permeability). These ben-
eﬁts were largely attributed to PDGFR inhibition. It is cur-
rently unknown why new-generation TKIs that also inhibit
PDGFR present opposite cardiovascular safety proﬁle and
this point needs to be elucidated.
New-generation BCR-ABL TKIs increase the risk of arterial
thromboembolismwith different clinical features (e.g., time-
to-event and absolute rate) and are associated with different
safety proﬁles, suggesting different pathways to explain the
pathophysiology. The safety proﬁle of nilotinib is mostly
characterized by impaired glucose and lipid metabolism.
However, both themolecularmechanism of these alterations
and their impact on the occurrence of arterial thrombosis are
unknown. Both dasatinib and ponatinib exhibit antiplatelet
effect, whereas it was recently suggested that nilotinib
potentially induces prothrombotic phenotype of platelets.
Based on the clinical characteristics and case reports, ather-
osclerosis appears the most plausible mechanisms by which
new-generationTKIs induce arterial thrombosis. However, in
vitro and in vivo studies of viability and functions of SMCs
and inﬂammatory cells demonstrate reassuring impact of
dasatinib and nilotinib, even if additional studies are
required to complete this evaluation. However, ﬁrst experi-
ments indicate that dasatinib, nilotinib, and ponatinib inﬂu-
ence EC survival and/or endothelium integrity, suggesting a
reasonable hypothesis by which new-generation TKIs induce
atherosclerosis development and, subsequently, arterial
thrombosis. Additional studies on the shedding of functional
extracellular vesicles by endothelial cells might be interest-
ing regarding their important role in coronary artery dis-
eases.142 Finally, the impact of new-generation TKIs on
human blood coagulation and ﬁbrinolysis has never been
studied and should be addressed.
To conclude, new-generation TKIs increase the risk of
arterial thrombosis in patients with CML, whereas imatinib,
the ﬁrst-generation TKI, might prevent the development of
cardiovascular events. To date, the cellular events and signal-
ing pathways by which these events occurred are unknown
and researches are extremely limited focusing mainly on
imatinib and nilotinib. Researches need to be extended to all
new-generation BCR-ABL TKIs (i.e., dasatinib, bosutinib, and
ponatinib). The understanding of the mechanisms by which
new-generation BCR-ABL TKIs induce or promote arterial
occlusive events will improve the clinical uses of these
therapies. To date, only general risk minimization measures
have been proposed (e.g., management of dyslipidemia,
aivDDR-1: Discoidin domain receptor tyrosine kinase 1. DDR1 is
involved in the regulation of cell growth, differentiation, and
metabolism.
av Tie-2: Tunica interna endothelial cell kinase. Tie-2 regulates
angiogenesis, endothelial cell survival, proliferation, migration,
adhesion and cell spreading, cytoskeleton reorganization, and
vascular quiescence. Tie-2 also possesses anti-inflammatory func-
tions by preventing the leakage of proinflammatory mediators and
leukocytes.
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diabetes, arterial hypertension following standard of
care).14,22,23,143–146 The understanding of the pathophysiol-
ogy is required to implement the most appropriate risk
minimization strategies for thrombotic events and to select
patients to whom the prescription of these drugs should be
avoided when applicable. Finally, the understanding of the
pathophysiology will help in the design of new BCR-ABL
inhibitors sparing the toxic targets.
Review Criteria
Relevant articles published from the database inception to
July 11, 2017, were identiﬁed from an electronic database
(PubMed) using the keywords “vascular,” “thrombosis,”
“atherosclerosis,” “arteriosclerosis,” “venous,” “arterial,”
“hemostasis,” “metabolic,” “metabolism,” “glycemia,” “gly-
caemia,” “cholesterol,” “triglycerides,” and “platelet” com-
bined with the ﬁve approved BCR-ABL TKIs. The search
strategy is presented in supplementary ﬁles. Articles pub-
lished in languages other than English were excluded from
the analysis. Primary criteriawere pathophysiological expla-
nation of arterial thrombotic events. Abstracts and full-text
articles were reviewedwith a focus on atherogenesis, plaque
rupture, platelet functions, and their link with the develop-
ment of arterial thrombosis with BCR-ABL TKIs. The refer-
ence section of identiﬁed articles was also examined.
Authors’ Contributions
H.H. was responsible for the ﬁrst draft of the manuscript.
F.M., C.C., C.G., J.M.D., and J.D. contributed to theﬁnal draft
of the manuscript.
Conﬂicts of Interest
J.D. reports personal fees from Roche Diagnostics, Stago
Diagnostica, Bayer Healthcare, and Daiichi-Sankyo; travel
grants from Bayer Healthcare, Boehringer Ingelheim, CSL
Behring, and Stago Diagnostica outside the submitted
work.
F.M. reports personal fees from Boehringer Ingelheim,
Bayer Healthcare, and Bristol-Myers Squibb-Pﬁzer out-
side the submitted work.
C.G. reports personal fees from Novartis, Celgene, and
Amgen outside the submitted work.
The other authors have no conﬂicts of interest to disclose.
References
1 Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E.
Management of imatinib-resistant patients with chronic mye-
loid leukemia. Ther Adv Hematol 2013;4(02):103–117
2 Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to
STI-571 cancer therapy caused by BCR-ABL gene mutation or
ampliﬁcation. Science 2001;293(5531):876–880
3 Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase
inhibitors in chronic myeloid leukemia and recent therapeutic
strategies to overcome resistance. Hematology (Am Soc Hematol
Educ Program) 2009;2009(01):461–476
4 Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results
of DASISION: the Dasatinib Versus Imatinib Study in Treatment-
Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016;
34(20):2333–2340
5 Hochhaus A, Saglio G, Hughes TP, et al. Long-term beneﬁts and
risks of frontline nilotinib vs imatinib for chronic myeloid
leukemia in chronic phase: 5-year update of the randomized
ENESTnd trial. Leukemia 2016;30(05):1044–1054
6 Brümmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus
imatinib in newly diagnosed chronic-phase chronic myeloid
leukaemia: results from the 24-month follow-up of the BELA
trial. Br J Haematol 2015;168(01):69–81
7 Mealing S, Barcena L, Hawkins N, et al. The relative efﬁcacy of
imatinib, dasatinib and nilotinib for newly diagnosed chronic
myeloid leukemia: a systematic review and network meta-
analysis. Exp Hematol Oncol 2013;2(01):5
8 Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. Mechanisms
of resistance to BCR-ABL and other kinase inhibitors. Biochim
Biophys Acta 2013;1834(07):1449–1459
9 Pagnano KB, Bendit I, Boquimpani C, et al; Latin American
Leukemia Net (LALNET). BCR-ABL mutations in chronic myeloid
leukemia treated with tyrosine kinase inhibitors and impact on
survival. Cancer Invest 2015;33(09):451–458
10 Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emer-
gence of BCR-ABL kinase domain mutations associated with
newly diagnosed chronic myeloid leukemia: a meta-analysis of
clinical trials of tyrosine kinase inhibitors. J Manag Care Spec
Pharm 2015;21(02):114–122
11 National Comprehensive Cancer Network. NCCNClinical Practice
Guidelines in Oncology: Chronic Myeloid Leukemia. Version
1.2017. 2016
12 Thanopoulou E, Judson I. The safety proﬁle of imatinib in CML and
GIST: long-term considerations. Arch Toxicol 2012;86(01):1–12
13 Kalmanti L, Saussele S, Lauseker M, et al. Safety and efﬁcacy of
imatinib in CML over a period of 10 years: data from the
randomized CML-study IV. Leukemia 2015;29(05):1123–1132
14 Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated
cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol
2015;33(35):4210–4218
15 Breccia M, Alimena G. Pleural/pericardic effusions during dasa-
tinib treatment: incidence, management and risk factors asso-
ciated to their development. Expert Opin Drug Saf 2010;9(05):
713–721
16 European Medicines Agency. Sprycel - Summary of Product Char-
acteristics2017. Available at: http://www.ema.europa.eu/docs/en
_GB/document_library/EPAR_-_Product_Information/human/000
709/WC500056998.pdf. Accessed December 22, 2017
17 European Medicines Agency. Iclusig - Summary of Product
Characteristics 2017. Available at: http://www.ema.europa.
eu/docs/en_GB/document_library/EPAR_-_Product_Informa-
tion/human/002695/WC500145646.pdf. AccessedDecember 22,
2017
18 European Medicines Agency. Tasigna - Summary of Product Char-
acteristics 2017. Available at: http://www.ema.europa.eu/docs/en
_GB/document_library/EPAR_-_Product_Information/human/000
798/WC500034394.pdf. Accessed December 22, 2017
19 Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and
management of toxicity in leukemia patients with resistance or
intolerance to imatinib and other tyrosine kinase inhibitors.
Blood 2014;123(09):1309–1318
20 Saglio G, Kim D-W, Issaragrisil S, et al; ENESTnd Investigators.
Nilotinib versus imatinib for newly diagnosed chronic myeloid
leukemia. N Engl J Med 2010;362(24):2251–2259
21 Poch Martell M, Sibai H, Deotare U, Lipton JH. Ponatinib in the
therapy of chronic myeloid leukemia. Expert Rev Hematol 2016;
9(10):923–932
22 Douxﬁls J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM.
Association between BCR-ABL tyrosine kinase inhibitors for
chronic myeloid leukemia and cardiovascular events, major
molecular response, and overall survival: a systematic review
and meta-analysis. JAMA Oncol 2016; doi: 10.1001/jamaoncol.
2015.5932
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e84
23 Haguet H, Douxﬁls J, Mullier F, Chatelain C, Graux C, Dogné JM.
Risk of arterial and venous occlusive events in chronic myeloid
leukemia patients treated with new generation BCR-ABL tyro-
sine kinase inhibitors: a systematic review and meta-analysis.
Expert Opin Drug Saf 2017;16(01):5–12
24 Cortes J, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efﬁcacy and
safety in heavily pretreated leukemia patients: 3-year results of
the PACE trial. 20th Congress of EHA; Copenhagen, Denmark,
June 12, 2015
25 Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kornowski
R, Raanani P. Tyrosine kinase inhibitor associated vascular toxi-
city in chronicmyeloid leukemia. Cardio-Oncology 2015;1(01):5
26 Gora-Tybor J, Medras E, Calbecka M, et al. Real-life comparison of
severe vascular events and other non-hematological complications
in patients with chronic myeloid leukemia undergoing second-line
nilotinib or dasatinib treatment. Leuk Lymphoma 2015;56(08):
2309–2314
27 le Coutre PD, Hughes TP, Mahon FX, et al. Low incidence of
peripheral arterial disease in patients receiving dasatinib in
clinical trials. Leukemia 2016;30(07):1593–1596
28 Sam PY, Ahaneku H, Nogueras-Gonzalez GM, et al. Cardiovas-
cular events among patients with chronic myeloid leukemia
(CML) treatedwith tyrosine kinase inhibitors (TKIs). Blood 2016;
128(22):1919
29 Lassila M, Allen TJ, Cao Z, et al. Imatinib attenuates diabetes-
associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004;
24(05):935–942
30 Ma LK, Li Q, He LF, et al. Imatinib attenuates myocardial ﬁbrosis
in association with inhibition of the PDGFRα activity. Arq Bras
Cardiol 2012;99(06):1082–1091
31 Fossard G, Blond E, Balsat M, et al. Hyperhomocysteinemia and
high doses of nilotinib favor cardiovascular events in chronic
phase chronic myelogenous leukemia patients. Haematologica
2016;101(03):e86–e90
32 Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal
bleeding in a chronic myeloid leukaemia patient precipitated by
dasatinib-induced platelet dysfunction: case report. Platelets
2015;26(08):809–811
33 Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP.
Dasatinib enhances megakaryocyte differentiation but inhibits
platelet formation. Blood 2011;117(19):5198–5206
34 Alhawiti N, Burbury KL, Kwa FA, et al. The tyrosine kinase
inhibitor, nilotinib potentiates a prothrombotic state. Thromb
Res 2016;145:54–64
35 Lotﬁ K, Deb S, Sjöström C, Tharmakulanathan A, Boknäs N,
Ramström S. Individual variation in hemostatic alterations
caused by tyrosine kinase inhibitors: a way to improve perso-
nalized cancer therapy? Blood 2016;128(22):1908
36 Li R, Grosser T, Diamond SL. Microﬂuidic whole blood testing of
platelet response to pharmacological agents. Platelets 2017;28
(05):457–462
37 Senis YA,Mazharian A, Mori J. Src family kinases: at the forefront
of platelet activation. Blood 2014;124(13):2013–2024
38 GratacapMP,Martin V, ValéraMC, et al. The new tyrosine-kinase
inhibitor and anticancer drugdasatinib reversibly affects platelet
activation in vitro and in vivo. Blood 2009;114(09):1884–1892
39 Albrecht-Schgoer K, Huber K, Grebien F, et al. Nilotinib exerts
direct pro-atherogenic and anti-angiogenic effects on vascular
endothelial cells: a potential explanation for drug-induced vas-
culopathy in CML. Blood 2013;122(21):257
40 Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M,
Scheid C, von Bergwelt-Baildon M. Improvement of platelet
dysfunction in chronic myelogenous leukemia following treat-
ment with imatinib: a case report. J Med Case Reports 2011;
5:215
41 Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J,
Milojkovic D. Platelet dysfunction associated with ponatinib, a
new pan BCR-ABL inhibitor with efﬁcacy for chronic myeloid
leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Haematologica 2012;97(09):1444
42 Loren CP, Aslan JE, Rigg RA, et al. The BCR-ABL inhibitor ponatinib
inhibits platelet immunoreceptor tyrosine-based activation
motif (ITAM) signaling, platelet activation and aggregate forma-
tion under shear. Thromb Res 2015;135(01):155–160
43 Rivera VM, Pritchard JR, Gonzalvez F, Baker T, Gozgit JM, Hodgson
G. Comparative TKI proﬁling analyses to explore potential
mechanisms of Ponatinib-associated arterial thrombotic events.
Blood 2014;124(21):1783
44 Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine
kinase inhibitor-induced platelet dysfunction in patients with
chronic myeloid leukemia. Blood 2009;114(02):261–263
45 Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G.
Imatinibmesylate may improve fasting blood glucose in diabetic
Phþ chronicmyelogenous leukemia patients responsive to treat-
ment. J Clin Oncol 2004;22(22):4653–4655
46 Breccia M, Alimena G. The metabolic consequences of imatinib
mesylate: changes on glucose, lypidic and bone metabolism.
Leuk Res 2009;33(07):871–875
47 Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine
kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on
bloodglucose levels indiabetic andnondiabetic patients ingeneral
clinical practice. J Oncol Pharm Pract 2011;17(03):197–202
48 Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A,
Alimena G. Fasting glucose improvement under dasatinib treat-
ment in an accelerated phase chronic myeloid leukemia patient
unresponsive to imatinib and nilotinib. Leuk Res 2008;32(10):
1626–1628
49 Ono K, Suzushima H, Watanabe Y, et al. Rapid amelioration of
hyperglycemia facilitated by dasatinib in a chronic myeloid
leukemia patient with type 2 diabetes mellitus. Intern Med
2012;51(19):2763–2766
50 Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse
type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S
A 2008;105(48):18895–18900
51 Hägerkvist R, Jansson L, Welsh N. Imatinib mesylate improves
insulin sensitivity and glucose disposal rates in rats fed a high-fat
diet. Clin Sci (Lond) 2008;114(01):65–71
52 Han MS, Chung KW, Cheon HG, et al. Imatinib mesylate reduces
endoplasmic reticulum stress and induces remission of diabetes
in db/db mice. Diabetes 2009;58(02):329–336
53 Hägerkvist R, Makeeva N, Elliman S, Welsh N. Imatinib mesylate
(Gleevec) protects against streptozotocin-induced diabetes and
islet cell death in vitro. Cell Biol Int 2006;30(12):1013–1017
54 Hägerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of
diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-
kappaB activation and anti-apoptotic preconditioning. FASEB J
2007;21(02):618–628
55 Xia CQ, Zhang P, Li S, et al. C-Abl inhibitor imatinib enhances
insulin production by β cells: c-Abl negatively regulates insulin
production via interfering with the expression of NKx2.2 and
GLUT-2. PLoS One 2014;9(05):e97694
56 Sadiq S, Owen E, Foster T, et al. Nilotinib-induced metabolic
dysfunction: insights from a translational pilot study using in
vitro adipocytemodels and patient cohorts. 22nd EHA congress;
June 22–25, 2017; Madrid, Spain
57 Iizuka K, Niwa H, Kato T, Takeda J. Dasatinib improves insulin
sensitivity and affects lipidmetabolism in a patient with chronic
myeloid leukaemia. BMJ Case Rep 2016;2016:201
58 Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino
AC. Plasma adiponectin levels aremarkedly elevated in imatinib-
treated chronic myeloid leukemia (CML) patients: a mechanism
for improved insulin sensitivity in type 2 diabetic CML patients?
J Clin Endocrinol Metab 2010;95(08):3763–3767
59 Hosch SE, Olefsky JM, Kim JJ. APPLied mechanics: uncovering
how adiponectin modulates insulin action. Cell Metab 2006;4
(01):5–6
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al. e85
60 Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regula-
tion and association to insulin sensitivity. Obes Rev 2005;6(01):
13–21
61 Fitter S, Vandyke K, Gronthos S, Zannettino AC. Suppression of
PDGF-induced PI3 kinase activity by imatinib promotes adipo-
genesis and adiponectin secretion. J Mol Endocrinol 2012;48
(03):229–240
62 Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive
peripheral arterial occlusive disease and other vascular events
during nilotinib therapy in CML. Am J Hematol 2011;86(07):
533–539
63 Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting
glucose level as metabolic side effect of nilotinib in non-diabetic
chronic myeloid leukemia patients resistant to imatinib. Leuk
Res 2007;31(12):1770–1772
64 Castagnetti F, Breccia M, Gugliotta G, et al; GIMEMA CMLWork-
ing Party. Nilotinib 300 mg twice daily: an academic single-arm
study of newly diagnosed chronic phase chronic myeloid leuke-
mia patients. Haematologica 2016;101(10):1200–1207
65 Delphine R, Gautier J-f, Breccia M, et al. Incidence of hypergly-
cemia by 3 years in patients (Pts) with newly diagnosed chronic
myeloid leukemia in chronic phase (CML-CP) treated with
Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Blood 2012;120
(21):1686
66 Iurlo A, Orsi E, Cattaneo D, et al. Effects of ﬁrst- and second-
generation tyrosine kinase inhibitor therapyon glucose and lipid
metabolism in chronic myeloid leukemia patients: a real clinical
problem? Oncotarget 2015;6(32):33944–33951
67 Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired
glucose metabolism during nilotinib therapy in patients with
chronic myelogenous leukemia. Haematologica 2013;98(10):
e124–e126
68 Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T.
Nilotinib exacerbates diabetes mellitus by decreasing secretion
of endogenous insulin. Int J Hematol 2013;97(01):135–138
69 Hadzijusufovic E, Herndlhofer S, Aichberger KJ, et al. Nilotinib
exerts direct effects on vascular endothelial cells andmayact as a
co-trigger of atherosclerosis in patients with Phþ CML. Blood
2011;118(21):2753
70 Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G. Nilotinib-
mediated increase in fasting glucose level is reversible, does not
convert to type 2 diabetes and is likely correlated with increased
body mass index. Leuk Res 2012;36(04):e66–e67
71 Saglio G, Larson RA, Hughes TP, et al. Efﬁcacy and safety of
Nilotinib in chronic phase (CP) chronic myeloid leukemia (CML)
patients (Pts) with type 2 diabetes in the ENESTnd trial. Blood
2010;116(21):3430
72 Frasca F, Pandini G, Malaguarnera R, et al. Role of c-Abl in
directing metabolic versus mitogenic effects in insulin receptor
signaling. J Biol Chem 2007;282(36):26077–26088
73 Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gam-
bacorti-Passerini C. Alterations in creatine kinase, phosphate
and lipid values in patients with chronic myeloid leukemia
during treatment with imatinib. Haematologica 2008;93(02):
317–318
74 Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipi-
demia. N Engl J Med 2005;353(25):2722–2723
75 Gologan R, Constantinescu G, Georgescu D, et al. Hypolipemiant
besides antileukemic effect of imatinibmesylate. Leuk Res 2009;
33(09):1285–1287
76 Ellis M, Krashin E, Hamburger-Avnery O, Gan S, Elis A, Ashur-
Fabian O. The anti-leukemic and lipid lowering effects of ima-
tinib are not hindered by statins in CML: a retrospective clinical
study and in vitro assessment of lipid-genes transcription. Leuk
Lymphoma 2017;58(05):1172–1177
77 Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D.
Incidence of type II diabetes mellitus and hyperlipidemia in
patients prescribed Dasatinib or Nilotinib as ﬁrst or second line
therapy for chronic myelogenous leukemia (CML). Blood 2016;
128(22):4766
78 Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholester-
olemia induced by the 2nd-generation tyrosine kinase inhibitor
nilotinib in patients with chronic phase-chronic myeloid leuke-
mia. Haematologica 2014;99(07):1197–1203
79 Maurizot A, Beressi JP, Manéglier B, et al. Rapid clinical improve-
ment of peripheral artery occlusive disease symptoms after
nilotinib discontinuation despite persisting vascular occlusion.
Blood Cancer J 2014;4:e247
80 Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors
impair metabolism and endocrine system function: a systematic
updated review. Leuk Res 2014;38(12):1392–1398
81 Venalis P, Maurer B, Akhmetshina A, et al. Lack of inhibitory
effects of the anti-ﬁbrotic drug imatinib on endothelial cell
functions in vitro and in vivo. J Cell Mol Med 2009;13(10):
4185–4191
82 Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reduces
viability, migration, and functionality of human endothelial
cells. Leuk Lymphoma 2017;58(06):1455–1467
83 Vallières K, Petitclerc E, Laroche G. On the ability of imatinib
mesylate to inhibit smooth muscle cell proliferation without
delaying endothelialization: an in vitro study. Vascul Pharmacol
2009;51(01):50–56
84 Hacker TA, Grifﬁn MO, Guttormsen B, Stoker S, Wolff MR.
Platelet-derived growth factor receptor antagonist STI571 (ima-
tinib mesylate) inhibits human vascular smooth muscle prolif-
eration and migration in vitro but not in vivo. J Invasive Cardiol
2007;19(06):269–274
85 Vrekoussis T, Stathopoulos EN, De Giorgi U, et al. Modulation of
vascular endothelium by imatinib: a study on the EA.hy 926
endothelial cell line. J Chemother 2006;18(01):56–65
86 Letsiou E, Rizzo AN, Sammani S, et al. Differential and opposing
effects of imatinib on LPS- and ventilator-induced lung injury.
Am J Physiol Lung Cell Mol Physiol 2015;308(03):L259–L269
87 Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung
vascular toxicity and predisposes to pulmonary hypertension.
J Clin Invest 2016;126(09):3207–3218
88 Rizzo AN, Sammani S, Esquinca AE, et al. Imatinib attenuates
inﬂammation and vascular leak in a clinically relevant two-hit
model of acute lung injury. Am J Physiol Lung Cell Mol Physiol
2015;309(11):L1294–L1304
89 Katgı A, Sevindik ÖG, Gökbulut AA, et al. Nilotinib does not alter
the secretory functions of carotid artery endothelial cells in a
prothrombotic or antithrombotic fashion. Clin Appl Thromb
Hemost 2015;21(07):678–683
90 Hadzijusufovic E, Kirchmair R, Theurl M, et al. Ponatinib exerts
multiple effects on vascular endothelial cells: possible
mechanisms and explanations for the adverse vascular events
seen in CML patients treated with Ponatinib. Blood 2016;128
(22):1883
91 Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human
endothelial cells in culture. Delayed replication, disturbed cell
cycle, and accelerated death. Diabetes 1985;34(07):621–627
92 Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmon-
ary arterial hypertension in patients receiving dasatinib. Am J
Hematol 2015;90(11):1060–1064
93 Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and
efﬁcacy of imatinib in pulmonary arterial hypertension.
J Heart Lung Transplant 2015;34(11):1366–1375
94 Dasgupta SK, Le A, Vijayan KV, Thiagarajan P. Dasatinib inhibits
actin ﬁber reorganization and promotes endothelial cell perme-
ability through RhoA-ROCK pathway. Cancer Med 2017;6(04):
809–818
95 Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB.
Imatinib inhibits the in vitro development of the monocyte/
macrophage lineage from normal human bone marrow progeni-
tors. Leukemia 2003;17(09):1713–1721
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e86
96 Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ.
Dasatinib is a potent inhibitor of tumour-associated macro-
phages, osteoclasts and the FMS receptor. Leukemia 2009;23
(03):590–594
97 Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits
the functional capacity of cultured human monocytes. Immunol
Cell Biol 2005;83(01):48–56
98 Dewar AL, Cambareri AC, Zannettino ACW, et al. Macrophage
colony-stimulating factor receptor c-fms is a novel target of
imatinib. Blood 2005;105(08):3127–3132
99 Metharom P, Martin K, Kumar AH, et al. Pleiotropic role for
monocyte C-fms protein in response to vascular injury: potential
therapeutic target. Atherosclerosis 2011;216(01):74–82
100 Gacic J, Vorkapic E, Olsen RS, et al. Imatinib reduces cholesterol
uptake and matrix metalloproteinase activity in human THP-1
macrophages. Pharmacol Rep 2016;68(01):1–6
101 Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the
activation and proliferation of normal T lymphocytes in vitro.
Leukemia 2004;18(08):1332–1339
102 Brownlow N, Russell AE, Saravanapavan H, et al. Comparison of
nilotinib and imatinib inhibition of FMS receptor signaling,
macrophage production and osteoclastogenesis. Leukemia
2008;22(03):649–652
103 Ozanne J, Prescott AR, Clark K. The clinically approved drugs
dasatinib and bosutinib induce anti-inﬂammatorymacrophages
by inhibiting the salt-inducible kinases. Biochem J 2015;465
(02):271–279
104 Darling NJ, Toth R, Arthur JS, Clark K. Inhibition of SIK2 and SIK3
during differentiation enhances the anti-inﬂammatory pheno-
type of macrophages. Biochem J 2017;474(04):521–537
105 Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-
molecule protein tyrosine kinase inhibitor, inhibits T-cell acti-
vation and proliferation. Blood 2008;111(03):1366–1377
106 Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family
kinase LCK and T-cell function in vitro. J Cell Mol Med 2009;13
(03):599–601
107 Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase
inhibitor dasatinib (BMS-354825) inhibits function of normal
human T-lymphocytes in vitro. Clin Immunol 2008;127(03):
330–339
108 Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers
MJ. Lck is a key target of imatinib and dasatinib in T-cell
activation. Leukemia 2010;24(04):896–900
109 Farha S, Dweik R, Rahaghi F, et al. Imatinib in pulmonary arterial
hypertension: c-Kit inhibition. Pulm Circ 2014;4(03):452–455
110 Juurikivi A, Sandler C, Lindstedt KA, et al. Inhibition of c-kit
tyrosine kinase by imatinib mesylate induces apoptosis in
mast cells in rheumatoid synovia: a potential approach to
the treatment of arthritis. Ann Rheum Dis 2005;64(08):
1126–1131
111 Sun YL, Kumar P, Sodani K, et al. Ponatinib enhances anticancer
drug sensitivity in MRP7-overexpressing cells. Oncol Rep 2014;
31(04):1605–1612
112 Yvan-Charvet L,WangN, Tall AR. Role of HDL, ABCA1, and ABCG1
transporters in cholesterol efﬂux and immune responses. Arter-
ioscler Thromb Vasc Biol 2010;30(02):139–143
113 Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-
derived growth factor-induced responses in vascular smooth
muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;
69(05):1527–1533
114 Nakamura K, Akagi S, Ogawa A, et al. Pro-apoptotic effects of
imatinib on PDGF-stimulated pulmonary artery smooth muscle
cells frompatients with idiopathic pulmonary arterial hyperten-
sion. Int J Cardiol 2012;159(02):100–106
115 Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential
effects of imatinib on PDGF-induced proliferation and PDGF
receptor signaling in human arterial and venous smooth muscle
cells. J Cell Biochem 2006;99(06):1553–1563
116 Rocha A, Azevedo I, Soares R. Anti-angiogenic effects of imatinib
target smooth muscle cells but not endothelial cells. Angiogen-
esis 2007;10(04):279–286
117 Ballinger ML, Osman N, Hashimura K, et al. Imatinib inhibits
vascular smoothmuscle proteoglycan synthesis and reduces LDL
binding in vitro and aortic lipid deposition in vivo. J Cell MolMed
2010;14(6B):1408–1418
118 Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces
production of extracellular matrix and prevents development of
experimental dermal ﬁbrosis. Arthritis Rheum 2007;56(01):
311–322
119 Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-
571) attenuates liver ﬁbrosis development in rats. Am J Physiol
Gastrointest Liver Physiol 2005;288(05):G907–G913
120 Salhotra A, Tsai N, Thomas SH, et al. Sclerodermatous chronic
GVHD in patients receiving tyrosine kinase inhibitors after
allogeneic hematopoietic cell transplantation. Bone Marrow
Transplant 2015;50(01):139–141
121 Makiyama Y, Toba K, Kato K, et al. Imatinib mesilate inhibits
neointimal hyperplasia via growth inhibition of vascular smooth
muscle cells in a rat model of balloon injury. Tohoku J Exp Med
2008;215(04):299–306
122 Park D, Kim SM,Min SI, Ha J, Kim IG,Min SK. Inhibition of intimal
hyperplasia by local perivascular application of rapamycin and
imatinib mesilate after carotid balloon injury. J Korean Surg Soc
2013;85(06):296–301
123 Leppänen O, Rutanen J, Hiltunen MO, et al. Oral imatinib
mesylate (STI571/Gleevec) improves the efﬁcacy of local intra-
vascular vascular endothelial growth factor-C gene transfer in
reducing neointimal growth in hypercholesterolemic rabbits.
Circulation 2004;109(09):1140–1146
124 Sevim KZ, Silistreli O, Gorgu M, Sevim O, Ergur B. Short-term
vasculoprotective effects of imatinib mesylate on intimal hyper-
plasia of arterial anastomosis: An experimental study using a
rabbit model. Can J Plast Surg 2012;20(04):223–228
125 Wu J, Chen Z, Bhalla KN. Treatment of restenosis and stenosis
with dasatinib (2014). USF Patents. 152
126 Sánchez-Ortega I, Servitje O, Arnan M, et al. Dasatinib as salvage
therapy for steroid refractory and imatinib resistant or intolerant
sclerotic chronic graft-versus-host disease. Biol Blood Marrow
Transplant 2012;18(02):318–323
127 Marinelli Busilacchi E, Olivieri J, Viola N, et al. The exaggerated
collagen expression in Gvhd-ﬁbroblasts is effectively inhibited
by therapeutic concentration of Nilotinib. Blood 2016;128(22):
4597
128 Shiha GE, Abu-Elsaad NM, Zalata KR, Ibrahim TM. Tracking anti-
ﬁbrotic pathways of nilotinib and imatinib in experimentally
induced liver ﬁbrosis: an insight. Clin Exp Pharmacol Physiol
2014;41(10):788–797
129 Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase
inhibitors in the treatment of chronic myeloid leukemia. Leuke-
mia 2009;23(10):1698–1707
130 Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic
proﬁles of the BCR-ABL inhibitors imatinib, nilotinib, and dasa-
tinib reveal novel kinase and nonkinase targets. Blood 2007;110
(12):4055–4063
131 Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and
their clinical relevance in myeloid disorders. Blood 2004;104
(07):1931–1939
132 Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative
chemical proteomics reveals mechanisms of action of clinical
ABL kinase inhibitors. Nat Biotechnol 2007;25(09):1035–
1044
133 Weisberg E, Manley PW, Breitenstein W, et al. Characterization
of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell 2005;7(02):129–141
134 Buchdunger E, Ciofﬁ CL, Law N, et al. Abl protein-tyrosine kinase
inhibitor STI571 inhibits in vitro signal transduction mediated
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al. e87
by c-kit and platelet-derived growth factor receptors.
J Pharmacol Exp Ther 2000;295(01):139–145
135 Manley PW, Drueckes P, FendrichG, et al. Extended kinase proﬁle
and properties of the protein kinase inhibitor nilotinib. Biochim
Biophys Acta 2010;1804(03):445–453
136 Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-
kinase interaction map for clinical kinase inhibitors. Nat Bio-
technol 2005;23(03):329–336
137 Shi H, Zhang CJ, Chen GY, Yao SQ. Cell-based proteome proﬁling
of potential dasatinib targets by use of afﬁnity-based probes.
J Am Chem Soc 2012;134(06):3001–3014
138 Liu Y,Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-β, and Abl
signaling and reduction of liver ﬁbrosis by the small molecule
Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011;55
(03):612–625
139 Sakamoto A, Sugamoto Y, Tokunaga Y, et al. Expression proﬁling
of the ephrin (EFN) and Eph receptor (EPH) family of genes in
atherosclerosis-related human cells. J Int Med Res 2011;39(02):
522–527
140 Khan AA, Sandhya VK, Singh P, et al. Signaling network map of
endothelial TEK tyrosine kinase. J Signal Transduct 2014;
2014:173026
141 Chislock EM, Ring C, Pendergast AM. Abl kinases are required for
vascular function, Tie2 expression, and angiopoietin-1-mediated
survival. Proc Natl Acad Sci U S A 2013;110(30):12432–12437
142 Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular
vesicles in coronary artery disease. Nat Rev Cardiol 2017;14
(05):259–272
143 Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-
ABL tyrosine kinase inhibitors in chronic myeloid leukemia:
preventive strategies and cardiovascular surveillance. Vasc
Health Risk Manag 2017;13:293–303
144 Damrongwatanasuk R, Fradley MG. Cardiovascular complica-
tions of targeted therapies for chronic myeloid leukemia. Curr
Treat Options Cardiovasc Med 2017;19(04):24
145 Valent P, Hadzijusufovic E, Hoermann G, et al. Risk factors and
mechanisms contributing to TKI-induced vascular events in
patients with CML. Leuk Res 2017;59:47–54
146 García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sán-
chez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. [Car-
diovascular management of patients with chronic myeloid
leukemia from a multidisciplinary perspective, and proposing
action protocol by consensus meeting]. Med Clin (Barc) 2016;
146(12):561.e1–561.e8
147 Aman J, van Bezu J, Damanafshan A, et al. Effective treatment of
edema and endothelial barrier dysfunction with imatinib. Cir-
culation 2012;126(23):2728–2738
148 Kim SR, Suh W. Beneﬁcial effects of the Src inhibitor, dasatinib,
on breakdown of theblood-retinal barrier. Arch PharmRes 2017;
40(02):197–203
149 Sukegawa M, Wang X, Nishioka C, et al. The BCR/ABL tyrosine
kinase inhibitor, nilotinib, stimulates expression of IL-1β in
vascular endothelium in association with downregulation of
miR-3p. Leuk Res 2017;58:83–90
150 Wolf AM,Wolf D, Rumpold H, et al. The kinase inhibitor imatinib
mesylate inhibits TNF-alpha production in vitro and prevents
TNF-dependent acutehepatic inﬂammation. ProcNatl Acad Sci U
S A 2005;102(38):13622–13627
151 Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball
JD. Dasatinib inhibits the secretion of TNF-alpha following TLR
stimulation in vitro and in vivo. Exp Hematol 2009;37(12):
1435–1444
152 Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell
receptor-mediated T-cell proliferation and activation in a dose-
dependent manner. Blood 2005;105(06):2473–2479
153 Dietz AB, Souan L, Knutson GJ, Bulur PA, LitzowMR, Vuk-Pavlovic
S. Imatinib mesylate inhibits T-cell proliferation in vitro and
delayed-type hypersensitivity in vivo. Blood 2004;104(04):
1094–1099
154 Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the pro-
liferation and function of CD8þ T lymphocytes through inhibi-
tion of T cell receptor signalling. J Cell Mol Med 2008;12
(5B):2107–2118
155 Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth
factor expression and function in idiopathic pulmonary arterial
hypertension. Am J Respir Crit Care Med 2008;178(01):81–88
156 Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN. Structural
mechanisms determining inhibition of the collagen receptor
DDR1 by selective and multi-targeted type II kinase inhibitors.
J Mol Biol 2014;426(13):2457–2470
157 Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-
ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma
2008;49(04):615–619
158 Remsing Rix LL, Rix U, Colinge J, et al. Global target proﬁle of the
kinase inhibitor bosutinib in primary chronic myeloid leukemia
cells. Leukemia 2009;23(03):477–485
159 Green MR, Newton MD, Fancher KM. Off-Target Effects of BCR-
ABL and JAK2 Inhibitors. Am J Clin Oncol 2016;39(01):76–84
TH Open Vol. 2 No. 1/2018
Thrombosis with BCR-ABL Tyrosine Kinases Inhibitors Haguet et al.e88
